Artificial selection

CENTOGENE wins digital health innovation award for leading artificial intelligence (AI) platform in biomarker discovery

Leveraging AI to Accelerate the Path from Diagnosis to Cure

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, December 23, 2021 (GLOBE NEWSWIRE) – Centogene NV (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven information to diagnose, understand and treat rare diseases, announced today that it has received the Health-i Award, which recognizes companies transforming healthcare in Germany and beyond.

The Health-i Awards are sponsored by Techniker Krankenkasse, Germany’s largest public health insurance provider, and Handelsblatt, one of Germany’s leading business newspapers. The Health-i Award winners were selected by industry and research experts for initiatives that are transforming the next era of healthcare through innovation.

CENTOGENE received the award based on its proprietary AI-based biomarker platform, CentoMetabolome. The internally deployed platform has the potential to revolutionize the detection of new biomarkers – speeding up research that previously took months to complete in just days. Use cases for the CentoMetabolome platform include supporting comprehensive metabolome screening, identifying candidate biomarkers, and building a better understanding of drug efficacy.

“We are proud to be recognized for our impact in the healthcare industry and for the innovation we bring with our unique Metabolomics Platform,” said Carsten Ullrich, Ph.D., Senior Director of Artificial Intelligence . “By working together in several departments, we have been able to take full advantage of CENTOGENE’s expertise in omics, the extensive global information from our database / bio focused on rare diseases and tools for Advanced AI. As a result, we can now analyze disease dynamics to drive biomarker discovery and test drug candidates as we continue our mission of healing 100 rare diseases in 10 years. “

The continued development of AI initiatives, such as CentoMetabolome, represents another important milestone for CENTOGENE’s mission to enable cures of 100 rare diseases over the next 10 years. To find out more visit:


CENTOGENE engages in the diagnosis and research around rare diseases by transforming clinical, genetic and multiomic data from the real world to diagnose, understand and treat rare diseases. Our goal is to streamline treatment decisions and accelerate the development of new orphan drugs using our extensive knowledge and data on rare diseases. CENTOGENE has developed a proprietary global rare disease platform based on our real world data repository of over 600,000 patients representing over 120 different countries.

The Company’s platform includes epidemiological, phenotypic and genetic data that reflect a global population, as well as a biobank of blood samples and cell cultures from patients. CENTOGENE believes it is the only platform focused on comprehensive, multi-level data analysis to improve understanding of rare inherited diseases. It enables better identification and stratification of patients and their underlying diseases to enable and accelerate the discovery, development and access to orphan drugs. As of December 31, 2020, the Company was collaborating with more than 30 pharmaceutical partners.

Follow us on LinkedIn

Forward-looking statements

This press release contains “forward-looking statements” within the meaning of US federal securities laws. Statements in this document that are not clearly historical in nature are forward-looking, and the words “anticipate”, “believe”, “continue”, “expect”, “estimate”, “intend” , “Project” and similar expressions and future or conditional verbs such as “will”, “would”, “should”, “could”, “wight”, “can” and “can” are generally intended to identify statements prospective. These forward-looking statements involve known and unknown risks, uncertainties and other important factors which may cause CENTOGENE’s actual results, performance or achievements to differ materially from future results, performance or achievements expressed or implied by the companies. forward-looking statements. . These risks and uncertainties include, but are not limited to, negative global economic conditions and continued instability and volatility in global financial markets, the effects of the COVID-19 pandemic on our business and operating results, possible changes in legislation, regulations and government policies, increasing competitive and consolidation pressures in our industry, the expense and uncertainty of regulatory approval, including from the United States Food and Drug Administration, our dependence on third parties and collaborative partners, including our ability to manage growth and enter into new client relationships, our reliance on the rare disease industry, our ability to manage our international expansion, our dependence on key personnel, our reliance on intellectual property protection, fluctuations in our results of operations due to the effect of foreign exchange rates, our ability to rationalize the use of cash, our need for additional financing and our ability to continue operations or other factors. For more information on the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as the risks associated with CENTOGENE’s business in general, see CENTOGENE’s risk factors stated. in CENTOGENE Form 20-F filed April 15, 2021, with the Securities and Exchange Commission (the “SEC”) and subsequent filings with the SEC. All forward-looking statements contained in this press release speak only as of the date hereof, and CENTOGENE specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or other.

Media contact:
Ben legg
Business communication
[email protected]

Lennart Streibel
Investor Relations
[email protected]

Stern IR
Brendan Payne
+1 (212) 698 8695
[email protected]